PURPOSE: To evaluate the effects of Triesence   (TRI), a new preservative-free @entity2713 approved by the U.S. Food and Drug Administration (FDA) for intraocular use, on @entity1 retina pigment epithelial ( @entity1 ) and @entity35 neurosensory (R28) cells in culture. METHODS: @entity1 and R28 cell cultures were treated 24 h with 1,000, 500, 200, or 100  g/mL of crystalline (cTRI) or 1,000, 500, or 200  g/mL of solubilized (sTRI). TRI was solubilized by centrifuging the drug, discarding the supernatant containing the vehicle and then resuspending the drug pellet in an equivalent amount of @entity3733 to achieve the same concentration as the commercial preparation. Percentage of cell viability (CV) was evaluated by a @entity3460 dye-exclusion assay. The mitochondrial membrane potential (/\  m) was analyzed with the JC-1 assay. The @entity522 /7 activity was measured by a fluorochrome assay. RESULTS: In the ARPE-19 cultures, the cTRI caused a decrease in CV at 1,000  g/mL (13.03  6.51; P<0.001), 500  g/mL (28.87  9.3; P<0.001), 200  g/mL (54.93  5.61; P<0.001), and 100  g/mL (82.53  0.65; P<0.005) compared with the untreated controls (96.98  0.16). In R28 cultures, the cTRI treatment also reduced CV values significantly (P<0.001) for the 1,000  g/mL (22.73  2.44), 500  g/mL (34.63  1.91), 200  g/mL (58.70  1.39), and 100  g/m (75.33  2.47) compared with the untreated controls (86.08  3.54). Once the TRI was solubilized (sTRI), the CV and /\  m remained similar to the untreated controls for both @entity1 and R28 cells. The sTRI treatment with 1,000, 500, and 200  g/mL increased in @entity522 /7 activity in @entity1 cells (P<0.01) and in R28 cells (P<0.05) compared with @entity3733 equivalent controls. CONCLUSION: The crystalline form of TRI (cTRI) can cause a significant decrease in CV to cultured retinal cells. Once the TRI is solubilized (sTRI), at the same concentrations, the cells remain viable with no decrease in CV or /\  m. The sTRI can, however, increase @entity522 /7 activity, thus suggesting some degree of apoptosis.

The effects of commercially available preservative-free FDA-approved XXXX (Triesence  ) on retinal cells in culture.

@entity1 :: ('9606', 'Species') :: ['human', 'ARPE-19'] @entity522 :: ('836', 'Gene') :: ['caspase-3'] @entity3733 :: ('MESH:D004121', 'Chemical') :: ['Dimethyl sulfoxide', 'dimethyl sulfoxide'] @entity3460 :: ('MESH:D014343', 'Chemical') :: ['trypan blue'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']
@entity2713 :: (MESH:D014221,Chemical) :: ['triamcinolone']
